Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah C Gilbert

Showing results (161-170 of 215) with videos related to

Pageof 22
Sort By:
Science Translational Medicine|July 28, 2021
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical modelsNeeltje van Doremalen, Jyothi N Purushotham, Jonathan E Schulz, et al.
The Lancet. Microbe|November 9, 2021
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trialMohammad Bosaeed, Hanan H Balkhy, Sultan Almaziad, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7Robert J Fischer, Neeltje van Doremalen, Danielle R Adney, et al.
Plos One|May 20, 2014
External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillanceSean C Murphy, Cornelus C Hermsen, Alexander D Douglas, et al.
Vaccine|January 26, 2006
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CSSusanna J Dunachie, Michael Walther, Jenni M Vuola, et al.
Ebiomedicine|March 1, 2022
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studiesAlexandra J Spencer, Susan Morris, Marta Ulaszewska, et al.
Malaria Journal|January 29, 2015
Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studiesSusanne H Hodgson, Alexander D Douglas, Nick J Edwards, et al.
Scientific Reports|November 10, 2019
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary CamelsNaif Khalaf Alharbi, Ibrahim Qasim, Abdulrahman Almasoud, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 25, 2011
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectorsSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
Pageof 22

Showing results (161-170 of 215) with videos related to

Sort By:
Pageof 22
Science Translational Medicine|July 28, 2021
Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical modelsNeeltje van Doremalen, Jyothi N Purushotham, Jonathan E Schulz, et al.
The Lancet. Microbe|November 9, 2021
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trialMohammad Bosaeed, Hanan H Balkhy, Sultan Almaziad, et al.
Biorxiv : the Preprint Server for Biology|January 27, 2021
Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccineYasunori Watanabe, Luiza Mendonça, Elizabeth R Allen, et al.
Biorxiv : the Preprint Server for Biology|March 24, 2021
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7Robert J Fischer, Neeltje van Doremalen, Danielle R Adney, et al.
Plos One|May 20, 2014
External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillanceSean C Murphy, Cornelus C Hermsen, Alexander D Douglas, et al.
Vaccine|January 26, 2006
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CSSusanna J Dunachie, Michael Walther, Jenni M Vuola, et al.
Ebiomedicine|March 1, 2022
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studiesAlexandra J Spencer, Susan Morris, Marta Ulaszewska, et al.
Malaria Journal|January 29, 2015
Increased sample volume and use of quantitative reverse-transcription PCR can improve prediction of liver-to-blood inoculum size in controlled human malaria infection studiesSusanne H Hodgson, Alexander D Douglas, Nick J Edwards, et al.
Scientific Reports|November 10, 2019
Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary CamelsNaif Khalaf Alharbi, Ibrahim Qasim, Abdulrahman Almasoud, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 25, 2011
Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectorsSusanne H Sheehy, Christopher J A Duncan, Sean C Elias, et al.
Pageof 22